• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

MHE State of the Industry survey: Healthcare disparities and racism

Publication
Article
MHE PublicationMHE December 2020
Volume 30
Issue 12

In this final part of a six-part series, most are neutral-to-negative on chance of meaningful change.

The vast majority (72%) of the respondents to our State of the Industry reader survey indicated that they believed that their organization had taken meaningful steps to address healthcare disparities and racism this year.

But there was less confidence when the respondents were asked about whether the 2020 focus on healthcare disparities and racism will result in meaningful change. Almost half (49%) were neutral, and 21% had low confidence about meaningful change and 14% had very low confidence. The proportion of respondents who were confident that meaningful change would occur was quite low: 15% rated their confidence in meaningful change as high and 2% rated it as very high.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.